MedTrace Logo

CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma

NCT06234319 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-03-05

No results posted yet for this study

Summary

This project intends to evaluate the role of C-X-C chemokine receptor type 4 (CXCR4) targeted PET/MRI integrated imaging in the grading and molecular typing of brain gliomas, using primary glioma patients as the research subjects and post-operative histopathological analysis as the reference, and to establish an evaluation model for the prognosis of primary glioma patients.

Conditions

Interventions

DIAGNOSTIC_TEST

CXCR4

Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.

Sponsors & Collaborators

  • Xiao Chen

    lead OTHER

Principal Investigators

  • Chen Xiao, Ph.D · Daping Hospital, Army Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06234319 on ClinicalTrials.gov